Literature DB >> 26301122

Human microbiome: From the bathroom to the bedside.

Stephen Malnick1, Ehud Melzer1.   

Abstract

The human gut contains trillions of bacteria, the major phylae of which include Bacteroidetes, Firmicutes, Actinobacteria and Proteobacteria. Fecal microbial transplantation (FMT) has been known of for many years but only recently has been subjected to rigorous examination. We review the evidence regarding FMT for recurrent Clostridium difficile infection which has resulted in it being an approved treatment. In addition there is some evidence for its use in both irritable bowel syndrome and inflammatory bowel disease. Further research is needed in order to define the indications for FMT and the most appropriate method of administration.

Entities:  

Keywords:  Clostridium difficile; Fecal microbial transplant; Indications; Metabolic disorders; Side-effects

Year:  2015        PMID: 26301122      PMCID: PMC4540710          DOI: 10.4291/wjgp.v6.i3.79

Source DB:  PubMed          Journal:  World J Gastrointest Pathophysiol        ISSN: 2150-5330


  55 in total

Review 1.  Gut microbiome, obesity, and metabolic dysfunction.

Authors:  Herbert Tilg; Arthur Kaser
Journal:  J Clin Invest       Date:  2011-06-01       Impact factor: 14.808

Review 2.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

3.  Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome.

Authors:  Anne Vrieze; Els Van Nood; Frits Holleman; Jarkko Salojärvi; Ruud S Kootte; Joep F W M Bartelsman; Geesje M Dallinga-Thie; Mariette T Ackermans; Mireille J Serlie; Raish Oozeer; Muriel Derrien; Anne Druesne; Johan E T Van Hylckama Vlieg; Vincent W Bloks; Albert K Groen; Hans G H J Heilig; Erwin G Zoetendal; Erik S Stroes; Willem M de Vos; Joost B L Hoekstra; Max Nieuwdorp
Journal:  Gastroenterology       Date:  2012-06-20       Impact factor: 22.682

Review 4.  Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection.

Authors:  Ethan Gough; Henna Shaikh; Amee R Manges
Journal:  Clin Infect Dis       Date:  2011-11       Impact factor: 9.079

Review 5.  Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.

Authors:  Christina M Surawicz; Lawrence J Brandt; David G Binion; Ashwin N Ananthakrishnan; Scott R Curry; Peter H Gilligan; Lynne V McFarland; Mark Mellow; Brian S Zuckerbraun
Journal:  Am J Gastroenterol       Date:  2013-02-26       Impact factor: 10.864

6.  Treatment of ulcerative colitis by implantation of normal colonic flora.

Authors:  J D Bennet; M Brinkman
Journal:  Lancet       Date:  1989-01-21       Impact factor: 79.321

7.  Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection.

Authors:  Eero Mattila; Raija Uusitalo-Seppälä; Maarit Wuorela; Laura Lehtola; Heimo Nurmi; Matti Ristikankare; Veikko Moilanen; Kimmo Salminen; Maaria Seppälä; Petri S Mattila; Veli-Jukka Anttila; Perttu Arkkila
Journal:  Gastroenterology       Date:  2011-12-07       Impact factor: 22.682

Review 8.  Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response.

Authors:  Gayatri Vedantam; Andrew Clark; Michele Chu; Rebecca McQuade; Michael Mallozzi; V K Viswanathan
Journal:  Gut Microbes       Date:  2012-03-01

9.  Diverticulitis after fecal microbiota transplant for C. difficile infection.

Authors:  Amar Mandalia; Colleen S Kraft; Tanvi Dhere
Journal:  Am J Gastroenterol       Date:  2014-12       Impact factor: 10.864

10.  Treatment of ulcerative colitis using fecal bacteriotherapy.

Authors:  Thomas J Borody; Eloise F Warren; Sharyn Leis; Rosa Surace; Ori Ashman
Journal:  J Clin Gastroenterol       Date:  2003-07       Impact factor: 3.062

View more
  2 in total

Review 1.  Gnotobiotic mouse model's contribution to understanding host-pathogen interactions.

Authors:  Klara Kubelkova; Milota Benuchova; Hana Kozakova; Marek Sinkora; Zuzana Krocova; Jaroslav Pejchal; Ales Macela
Journal:  Cell Mol Life Sci       Date:  2016-08-20       Impact factor: 9.261

Review 2.  Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin.

Authors:  Christopher Chang
Journal:  Clin Exp Gastroenterol       Date:  2018-09-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.